It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The spread of many infectious diseases relies on aerosol transmission to the respiratory tract. Here we design an intranasal mask comprising a positively-charged thermosensitive hydrogel and cell-derived micro-sized vesicles with a specific viral receptor. We show that the positively charged hydrogel intercepts negatively charged viral aerosols, while the viral receptor on vesicles mediates the entrapment of viruses for inactivation. We demonstrate that when displaying matched viral receptors, the intranasal masks protect the nasal cavity and lung of mice from either severe acute respiratory syndrome coronavirus 2 or influenza A virus. With computerized tomography images of human nasal cavity, we further conduct computational fluid dynamics simulation and three-dimensional printing of an anatomically accurate human nasal cavity, which is connected to human lung organoids to generate a human respiratory tract model. Both simulative and experimental results support the suitability of intranasal masks in humans, as the likelihood of viral respiratory infections induced by different variant strains is dramatically reduced.
The spread of many infectious diseases substantially relies on aerosol transmission to the respiratory tract. Here, the authors design an intranasal mask with the ability to intercept viral aerosols, entrap and inactivate virus, thus preventing respiratory tract infection.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Chinese Academy of Sciences, State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Beijing, China (GRID:grid.9227.e) (ISNI:0000000119573309); University of Chinese Academy of Sciences, School of Chemical Engineering, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419)
2 University of Chinese Academy of Sciences, School of Chemical Engineering, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419); Chinese Academy of Sciences, State Key Laboratory of Multiphase Complex Systems, Institute of Process Engineering, Beijing, China (GRID:grid.9227.e) (ISNI:0000000119573309)
3 Beijing University of Chemical Technology, Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing, China (GRID:grid.48166.3d) (ISNI:0000 0000 9931 8406)
4 Chinese Academy of Sciences, State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Beijing, China (GRID:grid.9227.e) (ISNI:0000000119573309)
5 Beijing Institute of Biotechnology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China (GRID:grid.418873.1)
6 Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China (GRID:grid.410740.6) (ISNI:0000 0004 1803 4911)
7 China Academy of Chinese Medical Sciences, Institute of Chinese Materia Medica, Beijing, China (GRID:grid.410318.f) (ISNI:0000 0004 0632 3409)
8 The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen Key Laboratory of Nanozymes and Translational Cancer Research, Department of Otolaryngology, Shenzhen Institute of Translational Medicine, Shenzhen, China (GRID:grid.452847.8) (ISNI:0000 0004 6068 028X)
9 Beihang University, Key Laboratory of Biomechanics and Mechanobiology, Ministry of Education Beijing Advanced Innovation Center for Biomedical Engineering School of Biological Science and Medical Engineering, Beijing, China (GRID:grid.64939.31) (ISNI:0000 0000 9999 1211)
10 Peking University First Hospital, Department of Pharmacy, Beijing, China (GRID:grid.411472.5) (ISNI:0000 0004 1764 1621); Peking University, Institute of Clinical Pharmacology, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319)
11 National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, Beijing, China (GRID:grid.410749.f) (ISNI:0000 0004 0577 6238)
12 Affiliated Quanzhou First Hospital of Fujian Medical University, Department of Breast Surgery, Quanzhou, China (GRID:grid.412636.4)